Krzysztof Rosadzinsk, MD
Rheumatology · Hyannis, MANPI 1538415526
Payments from drug & device makers
Across 425 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- Johnson & Johnson$633
- AstraZeneca$442
- UCB, Inc.$398
- Lilly USA, LLC$377
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,77098%
- Education$2002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 121 | $1,983 |
| Amgen | 81 | $1,388 |
| Johnson & Johnson | 14 | $633 |
| AstraZeneca(2 entities) | 15 | $442 |
| UCB, Inc. | 17 | $398 |
| Lilly USA, LLC | 22 | $377 |
| Boehringer Ingelheim | 10 | $366 |
| Mallinckrodt Hospital Products Inc. | 7 | $324 |
| Pfizer | 17 | $291 |
| Novo Nordisk | 13 | $263 |
| Sanofi | 9 | $256 |
| Novartis | 13 | $251 |
| E.r. Squibb & Sons, L.L.C. | 11 | $217 |
| GSK | 10 | $215 |
| Vertex | 4 | $208 |
| Fresenius Kabi USA, LLC | 8 | $204 |
| Genentech USA, Inc. | 6 | $182 |
| Sobi, Inc | 5 | $157 |
| Organon | 7 | $125 |
| Bristol Myers Squibb | 4 | $93 |
| Sandoz | 4 | $88 |
| Radius Health, Inc. | 2 | $66 |
| Medexus Pharma, Inc. | 5 | $61 |
| Tandem Diabetes Care, Inc. | 3 | $47 |
| Cequr Corporation | 1 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Bayer | 2 | $32 |
| Shire North American Group Inc | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Pacira Therapeutics, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Bioventus LLC | 1 | $20 |
| Valeritas, Inc. | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Merck | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,970 in reported general payments places this provider in the 70th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 178 | $1,279,007 |
| Humira(Cf) PenAdalimumab | 162 | $1,277,872 |
| Cimzia (2 Pack)Certolizumab Pegol | 58 | $390,908 |
| OtezlaApremilast | 83 | $389,937 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 43 | $306,615 |
| Orencia ClickjectAbatacept | 50 | $280,391 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $237,752 |
| Taltz AutoinjectorIxekizumab | 30 | $204,746 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 30 | $201,354 |
| Cosentyx Sensoready PenSecukinumab | 15 | $179,035 |
| XeljanzTofacitinib Citrate | 27 | $145,769 |
| Humira PenAdalimumab | 20 | $135,034 |
| Actemra ActpenTocilizumab | 45 | $120,196 |
| HumiraAdalimumab | 11 | $111,588 |
| Xeljanz XrTofacitinib Citrate | 17 | $94,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $398 | $390,90858 claims |
| AmgenOtezla | $1,388 | $389,93783 claims |
| PfizerXeljanz | $291 | $145,76927 claims |
| AbbVieHumira | $1,983 | $111,58811 claims |
| GSKBenlysta | $215 | $93,85820 claims |
| SanofiKevzara | $256 | $68,10316 claims |
| Medexus Pharma, Inc.Rasuvo | $61 | $15,02427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 265 rheumatology providers in Massachusetts.
Other rheumatology in Hyannis
- David BrownHyannis$56K
- John StoneBoston$7.1M
- Sebastian UnizonyBoston$4M
- Tuhina NeogiBoston$3.7M
- George TsokosBoston$3.1M
- Roberto CaricchioWorcester$2.8M
- Charles BirbaraWorcester$2.3M
- Tanya LaidlawBoston$1.7M
- Deepak RaoBoston$1.7M
- Katherine LiaoBoston$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.